News and Stories About targeted therapy

Editor’s note: You may have seen some news coverage about a new drug that targets mutant KRAS in patients with […]
READ MORE

Editor’s note: Today’s article looks back at scientific and clinical advances made in 2020 and kicks off our Year in […]
READ MORE

Editor’s note: Earlier this year, we featured Steven Merlin’s amazing dedication as a Pancreatic Cancer Action Network (PanCAN) volunteer and […]
READ MORE

About one in four pancreatic cancer patients have changes in their tumor that suggest certain treatments may work particularly well […]
READ MORE

A recent paper published in the prestigious journal Lancet Oncology showed that the Pancreatic Cancer Action Network’s (PanCAN) Know Your […]
READ MORE

The Pancreatic Cancer Action Network’s (PanCAN) Know Your Tumor® precision medicine service can help pancreatic cancer patients live longer. Know […]
READ MORE

Editor’s note: January is Pancreatic Cancer Clinical Trials Awareness Month. Today we share the experience of a stage IV pancreatic […]
READ MORE

The Food and Drug Administration (FDA) recently approved the treatment Lynparza® (olaparib) for use in a group of pancreatic cancer […]
READ MORE

Editor’s note: Want to be inspired? Keep reading for a new update on Earl Groce, a stage IV pancreatic cancer […]
READ MORE

Today the U.S. Food and Drug Administration (FDA) approved the targeted therapy Lynparza® (olaparib) for the treatment of patients who […]
READ MORE

Editor’s note: This article kicks off our 2019 Year in Review series – highlighting the research advancements that you – […]
READ MORE

Editor’s note: Mary Fox passed away in January 2020. We are grateful she allowed her story to be shared. In […]
READ MORE

The goal of cancer treatment is to identify – and attack – vulnerabilities that make cancer cells different from healthy […]
READ MORE

Editor’s note: We originally published this blog in 2017. Since then, there have been new developments related to BRCA and […]
READ MORE

Editor’s note: We are deeply saddened to share that Adam Deal died of pancreatic cancer in December 2020. His advocacy […]
READ MORE

The morning of Feb. 5, 2016, started like many for Gail. She got up early and headed to the gym […]
READ MORE

The name Earl Groce may sound familiar to you. In January 2018, the then two-and-a-half-year survivor lent his voice during […]
READ MORE

When Allison Perlis of Potomac, Md., first began experiencing symptoms of pancreatic cancer in early 2017, she dismissed them as […]
READ MORE

Editor’s note: Today’s edition of the 2018 Year in Review series features the 10 most popular news stories on the […]
READ MORE

Editor’s note: Welcome to the first article in our 2018 Year in Review series! Over the next couple weeks, we’ll […]
READ MORE

The U.S. Food and Drug Administration (FDA) approved Vitrakvi® (larotrectinib) today for the treatment of any locally advanced or metastatic solid tumor, […]
READ MORE

Before Allison Lippman of Dallas met her now-husband, she was not convinced she wanted to date anyone. “I was turning […]
READ MORE

This year, the Pancreatic Cancer Action Network (PanCAN) awarded eight prestigious research grants to scientists and clinicians in the United […]
READ MORE

In June 2014, David Wingo went to his doctor about abdominal pain. While investigating the pain, his doctor noticed a […]
READ MORE

In September 2015, Earl Groce returned home to North Carolina after driving 5,500 miles cross-country for his first trip to […]
READ MORE

The 2018 Gastrointestinal (GI) Cancers Symposium is taking place in San Francisco, Jan. 18 to 20. The meeting brings together […]
READ MORE

Editor’s note: This article is another installment in our “Year in Review” series recapping the year’s top stories in pancreatic […]
READ MORE

Editor’s note: This article is the first in our “Year in Review” series recapping the year’s top stories in pancreatic […]
READ MORE

Akshay Mehta, MD, was in the middle of performing an orthopedic surgery when his first pancreatic cancer symptom arose. “I […]
READ MORE

The so-called breast cancer genes BRCA1 and BRCA2 were originally found to increase a woman’s risk of breast cancer when […]
READ MORE

Thanks to the generosity of donors, we awarded our largest-ever grant of $2 million in 2016 to accelerate a large-scale […]
READ MORE

Two new research studies offer encouraging steps toward developing effective therapies to target the notoriously challenging RAS mutations. About 95 […]
READ MORE